BPC 157 does not need to be cycled and here's why

Most people who cycle peptides have never actually thought about why cycling works, and that gap matters because when you understand the mechanism, you stop applying rules that were never meant to apply to you.

So start at the top. Your brain monitors your blood chemistry constantly, and when it wants more growth hormone in circulation, it sends a signal down to your pituitary gland, which then releases a pulse of growth hormone into your blood. Peptides like Ipamorelin and GHRP-2 work by mimicking that signal. They bind to something called the ghrelin receptor, which is a protein that sits on the surface of pituitary cells and acts like a doorbell for growth hormone release. Every time you press that doorbell, the cell answers and releases growth hormone.

The problem is that cells are not designed to have their doorbell rung continuously.

When a receptor gets stimulated over and over without rest, the cell starts pulling that receptor off its surface and hiding it inside. This is called receptor downregulation, which is the cell's way of turning down the volume on a signal that keeps coming in too loud. Fewer receptors on the surface means less response to the same stimulus, and that is exactly what you see in the data. One study tracked this in humans over 16 weeks of continuous growth hormone peptide use and found the growth hormone response had dropped by roughly 45 percent from baseline. Then they stopped for four weeks and the response came all the way back, which tells you the receptor was not damaged, it was just temporarily withdrawn. Cycling is the practice of stopping before that withdrawal gets too deep, and resuming after the receptors come back to the surface.

That is the whole mechanism. And BPC-157 does not touch it.

BPC-157 is not a receptor agonist in the way GHRP-2 is. It does not work by sitting on a cell surface receptor and firing it repeatedly. Instead, it acts more like a text message than a phone call. It delivers information to the cell, the cell reads it and starts running programs based on that information, and then BPC-157 clears your system. In rats, the half-life is approximately 15 minutes. In dogs it drops to around 5 minutes. After seven consecutive days of daily dosing, there was zero measurable accumulation in the body and no reduction in biological response from day one to day seven, which means the system that receives BPC-157's signal did not fatigue the way a repeatedly stimulated receptor does.

What the signal actually does is worth understanding in detail, because this is where BPC-157 separates from almost everything else used for recovery.

In tendon fibroblasts, the cells responsible for rebuilding connective tissue, BPC-157 increased growth hormone receptor expression by 2.29 times at 24 hours and up to 7 times by day three. That means BPC-157 is not delivering growth hormone or pretending to be growth hormone. It is turning up the volume on the cells that listen for growth hormone, so that your own circulating growth hormone does more work than it otherwise would. This was replicated independently at Chang Gung University in Taiwan, which gives it more weight than a single-lab finding.

BPC-157 also activates what is called the VEGFR2-Akt-eNOS signaling axis, which is a chain of molecular switches that drives angiogenesis, the formation of new blood vessels, and increases nitric oxide production to improve blood flow to damaged tissue. The compound is not doing the repair. It is switching on the programs that direct your body to do the repair, and then it leaves.

That distinction explains the most striking data point in this entire space. In a rat spinal cord injury model, a single injection of BPC-157 produced functional improvements that lasted 360 days, which is nearly the entire lifespan of the animal. The peptide was out of the bloodstream in minutes. The repair it initiated continued for over a year. A receptor agonist cannot do that because its effect ends when it leaves the receptor. BPC-157's effect persists because it changed the downstream programs, not the receptor availability.

Now the honest version of this requires a caveat, and it is worth taking seriously.

No study has been specifically designed to test whether BPC-157 builds tolerance over long-term continuous use in humans. That study does not exist yet. What does exist is evidence that BPC-157 interacts with dopamine, serotonin, GABA, and glutamate systems in the brain, and that some of those effects differ depending on whether exposure is acute or chronic. The interaction is bidirectional, meaning the direction of the effect can flip depending on context, which is a signal that the neurotransmitter effects are more complex than the tissue repair effects. The receptor desensitization mechanism that makes cycling necessary for growth hormone peptides does not apply here. But the absence of that specific mechanism is not the same as a guarantee that no other form of adaptation occurs with indefinite use.

The practical implication of all of this is actually simpler than the science.

Use BPC-157 for the problem you are trying to solve, whether that is tendon repair, gut lining repair, injury recovery, or something else. Run it until the problem resolves. Stop when the job is done, not because you are protecting a receptor, because there is no receptor at risk. If the same problem comes back months later, run it again. The biology supports that approach directly. Seven days of daily dosing produced the same response on day seven as it did on day one, which means the system does not desensitize on the timescale most people are using it.

The deeper insight here is that cycling is a receptor protection strategy, and whether you need it depends entirely on whether the compound works through receptor saturation. Most people never learned to ask that question. They learned that cycling is responsible, and they applied it everywhere. But responsible use means matching the rule to the mechanism, not applying every rule to every compound. BPC-157 is not a signal that wears out its welcome. It sends a message, the cell acts on it, and by the time the cell is doing the work, the peptide is already gone.

---

References

1. Liang et al., 2022, Frontiers in Pharmacology — BPC-157 pharmacokinetics in rats and dogs: half-life \~15 min rats, \~5 min dogs, no accumulation with 7-day repeated dosing. Source
2. Perovic et al., 2019, Journal of Orthopaedic Surgery and Research — Single BPC-157 injection produced functional recovery lasting 360 days in rat spinal cord injury model. Source
3. Chang et al., 2014, Molecules — BPC-157 upregulated growth hormone receptor expression 2.29-fold at 24h and up to 7-fold by day 3 in tendon fibroblasts independently replicated at Chang Gung University, Taiwan. Source
4. Hsieh et al., 2017, Journal of Molecular Medicine — BPC-157 activates VEGFR2-Akt-eNOS signaling axis, driving angiogenesis and nitric oxide production. Source
5. Sikiric et al., 2022, Neural Regeneration Research — BPC-157 modulates dopamine, serotonin, GABA, and glutamate systems with bidirectional effects depending on acute vs chronic administration. Source
6. Xu et al., 2020, Regulatory Toxicology and Pharmacology — Preclinical safety evaluation: no lethal dose identified, no toxic dose identified, no teratogenic or genotoxic effects across multiple species. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness